231 related articles for article (PubMed ID: 26376374)
1. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Q; Li S; Li L; Li Y; Sun X; Tian H
Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
[TBL] [Abstract][Full Text] [Related]
2. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
4. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
5. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
Lu B; Sun L; Seraydarian M; Hoffmann TJ; Medina MW; Risch N; Iribarren C; Krauss RM; Oni-Orisan A
Clin Pharmacol Ther; 2021 Sep; 110(3):733-740. PubMed ID: 34114646
[TBL] [Abstract][Full Text] [Related]
6. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
7. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
Carr DF; O'Meara H; Jorgensen AL; Campbell J; Hobbs M; McCann G; van Staa T; Pirmohamed M
Clin Pharmacol Ther; 2013 Dec; 94(6):695-701. PubMed ID: 23942138
[TBL] [Abstract][Full Text] [Related]
8. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
[TBL] [Abstract][Full Text] [Related]
9. SLCO1B1 variants and statin-induced myopathy.
Vladutiu GD; Isackson PJ
N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
[No Abstract] [Full Text] [Related]
10. [Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy].
Dendramis G
G Ital Cardiol (Rome); 2011 Mar; 12(3):182-5. PubMed ID: 21560474
[TBL] [Abstract][Full Text] [Related]
11. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
[TBL] [Abstract][Full Text] [Related]
12. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS.
Dheyaa Aziz N; Abbood SH; Al-Mayali AH; Hadi NR
Pol Merkur Lekarski; 2023; 51(5):496-503. PubMed ID: 38069850
[TBL] [Abstract][Full Text] [Related]
13. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
Santos PC; Gagliardi AC; Miname MH; Chacra AP; Santos RD; Krieger JE; Pereira AC
Eur J Clin Pharmacol; 2012 Mar; 68(3):273-9. PubMed ID: 21928084
[TBL] [Abstract][Full Text] [Related]
14. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy.
Turongkaravee S; Jittikoon J; Lukkunaprasit T; Sangroongruangsri S; Chaikledkaew U; Thakkinstian A
Pharmacogenomics J; 2021 Jun; 21(3):296-307. PubMed ID: 33608664
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics and adverse drug reactions: the case of statins.
Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
[TBL] [Abstract][Full Text] [Related]
17. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
18. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
Ferrari M; Guasti L; Maresca A; Mirabile M; Contini S; Grandi AM; Marino F; Cosentino M
Eur J Clin Pharmacol; 2014 May; 70(5):539-47. PubMed ID: 24595600
[TBL] [Abstract][Full Text] [Related]
19. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
[TBL] [Abstract][Full Text] [Related]
20. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]